Phase 2 Studies of Ultrafast PH20 Insulin Analogs for Type 1 and 2 Diabetes

Halozyme announced positive results from two Phase 2 studies evaluating ultrafast PH20 insulin analog formulations in patients with Type 1 and 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to the insulin analog comparator, with superior reductions in post-prandial glucose excursions in the PH20 insulin analog arms. Compared to insulin analog alone, PH20 insulin analog use resulted in a >50% increase in the proportion of patients able to consistently achieve AACE (American Association of Clinical Endocrinologists) guidelines for post-prandial glucose targets in both Type 1 and Type 2 patients. Across all of the treatment groups, there was no meaningful difference in hypoglycemia incidence or event rates.

For more information call (858) 794-8889 or visit